Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDP-323 in RSV infection
NCT06170242Phase 2Completed
- Sponsor
- Enanta Pharmaceuticals
- Start
- Nov 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of EDP-323 in respiratory syncytial virus infection (RSV), sponsored by Enanta Pharmaceuticals. Started Nov 2023; status: completed.
02
Drugs
EDP-323
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06170242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06170242.